politics
Eli Lilly Acquires AtaiBeckley, Signaling Growth in Psychedelic Drug Market
19 Temmuz 2026CNBC
- Eli Lilly has made a significant move by acquiring AtaiBeckley, a psychedelic drug maker, signaling a growing acceptance of psychedelic medications in the mental health treatment landscape. This acquisition highlights Big Pharma's increasing interest in a previously stigmatized class of drugs.
- The shift may pave the way for broader research and development in the field of psychedelics for mental health conditions.
- Psychedelic drugs have been historically associated with counterculture movements and have faced significant regulatory hurdles. However, recent studies have shown promising results in their effectiveness for conditions like depression and PTSD, leading to a reevaluation of their therapeutic potential.
- The acquisition by Eli Lilly represents a pivotal moment in the pharmaceutical industry's approach to mental health treatment. By embracing psychedelics, traditionally viewed with skepticism, Big Pharma is not only acknowledging the potential efficacy of these substances but also responding to a rising demand for in…
NewsAI özeti
This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for medical concerns.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.